KRAS & NRAS MUTATION ANALYSIS PANEL

RAS mutations are commonly found in cancer tissue, causing a permanent activation of the signal transduction pathway downstream of the EGF receptor (EGFR), thus positive signaling for cell growth. Most frequent are KRAS mutations in codons 12,13 in the second (first transcribed) exon. Up to 45% of all colorectal cancer patients exhibit KRAS 12,13 mutations, while another 10-15% may have mutations in KRAS exons 3 and 4 or in the respective regions of the homologous NRAS gene.

  • Test Type:
  • Pre-test Information:
    The submitted paraffin block must have atleast 10% tumor tissue
  • Report Delivery:
    Sample by Tue 11 am; Report Mon
  • Components:
    0

Sample Report